系统免疫炎症指数在心血管疾病中临床应用的研究进展
The Clinical Application Research Progress of the Systemic Immune Inflammation Index in Cardiovascular Diseases
DOI: 10.12677/acm.2024.1441240, PDF, HTML, XML,   
作者: 刘史红*, 高 燕:延安大学附属医院心脑血管病医院,陕西 延安
关键词: 系统免疫炎症指数心血管病预后Systemic Immune Inflammatory Index Cardiovascular Disease Prognosis
摘要: 系统免疫炎症指数(systemic immunoinflammatory index, SII)是一种基于中性粒细胞、血小板和淋巴细胞计数的新型炎症标志物,其可有效且全面的反映出机体炎症状态及免疫系统状况。近年来,有许多的研究表明,SII与多种心血管疾病(cardiovascular disease, CVD)的病理生理及预后具有相关性。本文就目前SII在CVD中的临床研究进展进行综述。
Abstract: The systemic immunoinflammatory index (SII) is a novel inflammatory marker based on neutrophil, platelet and lymphocyte counts, which can effectively and comprehensively reflect the inflammatory state and immune system status of the body. In recent years, many studies have shown that SII with various cardiovascular disease (CVD), physiological pathology and prognosis of correlation, this paper summarized research progress on currently SII in CVD in clinic.
文章引用:刘史红, 高燕. 系统免疫炎症指数在心血管疾病中临床应用的研究进展[J]. 临床医学进展, 2024, 14(4): 1885-1891. https://doi.org/10.12677/acm.2024.1441240

1. 引言

心血管疾病(cardiovascular disease, CVD)是全球最常见的非传染性疾病,估计在2017年造成1770万人死亡 [1] 。当前,随着我国人口老龄化及城镇化进程加快,居民不良生活方式的影响,心血管病危险因素对健康的影响越加显著,其发病率仍持续增高。2020年,CVD是我国城乡居民的首要死亡原因,农村为48.00%,城市为45.86%。为我国居民及社会带来的经济负担日渐加重,已成为重大的公共卫生问题 [2] 。CVD的防控、心血管急重症患者社会医疗资源的投入、降低CVD存活患者复发、再住院和失能的风险 [3] ,成为了我国医疗服务迫切需要解决的问题。疾病的诊治重点从疾病本身向疾病预防和健康促进转变。由于目前血清学标志物受当地医院实验室水平及辅助检查医院等级的限制,基层居民CVD就诊更多是因为严重的心脑血管并发症。因此,尽早识别CVD发生的相关因素显得极为重要。大量证据表明,慢性低度炎症在动脉粥样硬化和心血管疾病的发病机制中起着关键作用 [4] ,血管内皮损伤、氧化应激、血栓形成可能是潜在的潜在机制,全血细胞计数成分可作为冠心病风险预测因子 [5] ,淋巴细胞也参与了动脉粥样硬化的适应性免疫 [6] 。Bo Hu等人在2014年开发出系统免疫炎症指数(SII) = 为血小板数 × 中性粒细胞数/淋巴细胞计数的比值,最初被证明是预测肝癌的预后 [7] ,是一种结合淋巴细胞计数、中性粒细胞及血小板的新型炎症指数,其可有效且全面的反映出机体炎症状态及免疫系统状况。后被临床广泛研究并证明为呼吸系统肿瘤、消化系统肿瘤、妇科肿瘤及炎症性疾病的预后标志物 [8] [9] [10] [11] 。随后SII被应用于CVD的预后研究中,M. Xu等人进行了一项队列研究,纳入了13,929名平均年龄为62.56岁(范围35~91岁)且没有心血管疾病和癌症的中老年人进行分析。在中位8.28年(最长8.98年)的随访中,共发现了3386例心血管疾病病例,包括801例中风病例和2585例冠心病病例 [12] 。经过多变量Cox回归分析后发现,高SII与CVD事件(包括中风和冠心病)显著相关。SII可作为中老年人群心脑血管疾病发展中的作用的有用标志物。本文通过检索近年来SII与CVD相关及预后的文献,对其研究进展进行综述。

2. SII与心血管疾病

2.1. SII与高血压

高血压(Hypertension, HTN)是以体循环动脉压升高为主要临床表现的心血管综合征。即诊室收缩压 ≥ 140 mmHg和(或)舒张压 ≥ 90 mmHg。应至少通过2~3次就诊来确认,除非第一次就诊时记录的血压值显著升高3级高血压(≥180/100mmHg),或CVD风险高,包括高血压介导的靶器官损害的存在 [13] 。并发症包括脑卒中、冠心病、心力衰竭、慢性肾衰竭和主动脉夹层。致残和致死率高,已成为我国家庭和社会的沉重负担 [14] 。因此调查高血压的危险因素和有效预测因素,以减轻公共卫生负担十分重要。多种研究表明,HTN的发生发展涉及炎症,免疫,代谢的相互作用 [15] [16] ,HTN是一种动脉粥样硬化性和慢性炎症性疾病,持续的炎症状态与较差的预后相关 [17] 。白细胞及其各种亚群以及血小板是全身炎症状态不可或缺的成分。Jin N. [18] 等人进行一项横断面研究发现,与非高血压患者相比,高血压患者的SII水平显著升高。揭示了SII与高血压患病率之间的显着正相关。Lnanc [19] 等发现新诊断初治高血压患者的高SII与无症状器官损害(Asymptomatic Organ Damage, AOD)指标呈正相关。证实了高SII值是新诊断初治HTN患者AOD存在和严重程度的独立预测因子。此外,还有研究表明,与北斗七星高血压患者相比,非北斗七星高血压患者的SII水平明显更高,SII是非北斗七星高血压的独立预测因子 [20] ,非北斗七星高血压模式与北斗七星高血压相比,与更多的终末器官损伤和心血管事件相关,这与lnanc等研究结果一致。SII与高血压病发生发展存在相关性,并可作为预测因子评估其不良预后。

2.2. SII与动脉粥样硬化

动脉粥样硬化(atherosclerosis, AS)是冠心病、脑血管病和血栓栓塞性疾病等缺血性心脑血管病的主要病理基础 [21] 。本病发展到有器官明显病变时诊断并不困难,但早期诊断不易,对高危患者的早期识别并进行防治也是目前临床工作的难点。本病的发病机制尚不明确,AS最初被认为是动脉壁的脂质浸润 [22] ,后来被ROSS教授 [23] 认为AS是一种慢性炎症性疾病。越来越多的证据表明,动脉粥样硬化是一种缓慢而持续的炎症过程,伴随着多种炎症细胞的聚集,包括巨噬细胞、中性粒细胞、淋巴细胞和血小板 [24] 。血小板不仅参与急性血栓性血管闭塞,而且还参与早期的发生于血管壁中的慢性炎症,导致晚期动脉粥样硬化病变的不稳定 [25] 。有研究发现,高水平SII值与急性缺血性脑卒中的风险增加有关,并且SII是卒中严重程度的独立危险因素。SII在高血压患者颈动脉内膜中层厚度较高的患者中显著升高 [26] ,而颈动脉内膜中层厚度是亚临床动脉粥样硬化和内皮功能障碍的标志物。随着研究的不断深入,在新发动脉粥样硬化疾病(coronary artery disease, CAD)患者中,中性粒细胞数目大量增加并在主动脉粥样硬化斑块病变中大量存在,且与冠心病(coronary heart disease, CHD)的发病有关 [27] 。冠心病是冠状动脉粥样硬化硬化导致器官病变最常见的类型,严重危害人类健康。国内闵轩等人在回顾性研究中连续纳入6046例CAD患者,收集临床资料及冠状动脉血管成像结果,Gensini评分定量评估冠状动脉狭窄程度。根据Gensini评分三分位数分为:低值组(<11分,2011例)、中值组(11~38分,2018例)和高值组(>38分,2017例),结果显示经控制混杂因素后,CAD患者的SII与Gensini评分呈显著独立正相关 [28] 。SII可作为冠脉病变严重程度的独立危险因素。

2.3. SII与急性心肌梗死

急性心肌梗死(acute myocardial infarction, AMI)是CHD各种亚型中预后较差的类型。是在冠脉病变基础上,不稳定斑块破裂、糜烂继发血栓形成导致冠脉血供闭塞。2002~2018年AMI死亡率总体呈上升态势 [2] ,不及时开通梗死相关血管,恢复血供,可以并发心律失常、心力衰竭、心源性休克等危及生命的重症情况。寻找一个可以早期预测冠脉病变程度及相应干预措施的指标十分重要。在急性ST段抬高型心肌梗死(acute ST-segment elevation myocardial infarction, ASTEMI)发生、发展过程中,由于血管急剧闭塞导致心肌缺血,多种细胞毒因子及炎症介质,引发血管通透性增加而导致组织间质水肿,心肌水肿进一步限制了心肌的血流和心肌的营养供给而恶化了缺血后缺血局部的微环境 [29] 。微血管通透性改变亦是该病发生的重要机制。SII是一种结合淋巴细胞计数、中性粒细胞及血小板的新型炎症指数,可有效且全面的反映出机体炎症状态及免疫系统状况。近年有研究表明,SII可评估AMI患者的预后。Huang [30] 等人评估了SII在接受经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)的老年急性心肌梗死(AMI)患者的住院和长期预后方面的效用,发现SII是住院内及长期随访期间发生全因死亡/严重心脑血管不良事件(major adverse cardiovascular and cerebrovascular events, MACCE)的独立预测因子。一项对急性非ST段抬高型心肌梗死(Non-ST-segment elevation myocardial infarction, NSTEMI))的患者接受PCI治疗后的SII相关性研究 [31] 表明,高SII是NSTEMI患者冠状动脉血栓负荷的预测因子。刘诗彤 [32] 在研究中发现SII是与急性STEMI患者首次PCI术后慢血流/无复流发生相关的独立预测因子。此外SII可预测STEMI及NSTEMI患者PCI术后发生造影剂肾病(Contrast-media induced nephropathy, CIN)风险的发生 [33] [34] 。在临床工作中,SII可作为AMI预后的参考指标。

2.4. SII与心力衰竭

心力衰竭(heart failure, HF)是一种复杂的临床综合征,其症状和(或)体征由心脏结构和(或)功能异常引起,并由利钠肽水平升高和(或)肺(或)全身充血的客观证据证实 [35] 。心力衰竭是CVD的终末阶段,其死亡率与癌症相当 [2] ,已经成为影响居民健康的重要公共卫生问题,根据心衰发生的时间和速度可以分为慢性心衰(chronic heart failure, CHF)和急性心衰(acute heart failure, AHF)。AHF有两种形式:一种是慢性心衰的症状或体征突然恶化或急性加重,称为“急性失代偿性心力衰竭(acute decompensated heart failure, ADHF)”,是AHF的主要形式之一,约占80%~90%;另一种是既往有或无基础心脏病患者由于基础心脏病加重或急性心脏病变出现,抑或非心脏因素导致的首次发作,称为“新发的急性心力衰竭”,约占10%~20% [36] ,根据患者初次评估时超声心动图检查的左心室射血分数(LVEF)水平,心衰可以分为三种基本类型:“射血分数降低的心力衰竭(heart failure with reduced ejection, HFrEF)”、“射血分数轻度降低的心力衰竭(heart failure with mildly reduced ejection fraction, HFmrEF)”和“射血分数保留的心力衰竭(heart failure with preserved ejection fraction, HFpEF)” [35] 。有研究表明,急性心力衰竭5年全因死亡率为55.4% [37] 。因此有效的指标来预测HF患者死亡风险以指导治疗十分的重要 [38] 。脑利钠肽(B-type Natriuretic Peptide, BNP)可评估HF预后 [39] ,但受年龄、体重、肾功能等方面的影响 [40] 。有研究发现,炎症反应与心力衰竭的发生发展过程、病情严重程度及预后密切相关 [41] 。SII可综合反映血小板、中性粒细胞和淋巴细胞的状况,Miao Yuan [42] 等人回顾性纳入9107名HF患者,通过kaplan-meier曲线及Cox比例风险回归模型分析SII与全因死亡率的相关性,结果表明SII越高的组患者合并感染的可能性越高,其随访30、60、180、365天的死亡率也越高。而且在同一随访时间,心力衰竭患者的死亡风险随着入院时SII值的增加而增加,这表明高SII是心衰患者死亡率的独立预测因子。我国黎晨辉 [43] 等回顾性分析452名慢性心力衰竭急性发作(acute attack of chronic heart failure, ACHF)患者,多因素Logistic分析后提示BNP、NLR、PLR和SII水平的高低与ACHF患者的预后密切相关。通过ROC曲线分析后,SII对ACHF院内死亡的预测价值更优,且当SII ≥ 695.30时患者院内死亡的可能性越大。随着心肌梗死后幸存者数量的显著增加 [44] ,老年HFrEF病人逐年增加。杨少琦 [45] 等人还发现SII水平可作为老年HFrEF病人下肢深静脉血栓形成的独立预测因子,用其进行危险分层有助于早期识别高危人群。SII可以作为HF预后的预测因子。

2.5. SII与心源性休克

心源性休克(cardiogenic shock, CS)是一种复杂的临床综合征,由于原发性心脏疾病和(或)功能异常引起的心输出量降低或不足导致严重的终末器官低灌注和缺氧状态,常导致多器官衰竭和死亡 [46] 。急性心肌梗死是引起心源性休克最常见的病因,约占所有心源性休克的80%。但慢性心力衰竭急性失代偿导致的CGS病例比例越来越高 [47] 。在急性心肌梗死中, 心源性休克发生率在5%~10% [48] ,早期血运重建和现代重症监护的结果有所改善,但发病率和死亡率仍然很高,CS不仅是一种低灌注状态,而且与炎症有关 [49] 。Peng [50] 等人回顾性纳入707名CS患者,研究SII与患者死亡率相关性,结果表明高SII水平(>111.7)与CGS患者30天、90天或365天死亡率增加相关。高SII水平的CS患者在短期内(30天)死亡风险增加更为明显。SII可以独立预测CS患者的预后。

3. 展望

目前,随着居民物质条件进步和人均预期寿命提高,CVD仍是阻碍生活质量的首要病因。CVD包含多种疾病,且临床表现多以其他系统的症状。但早期诊断十分困难,很容易被临床医生误诊,延误治疗。SII通过血常规结果计算便可得出,是一个低廉、高效、易获取的新型炎症指数。SII可以预测CVD的不良预后及疾病严重程度,在常规检查中发现高SII患者,可以采取个体化干预措施,建议改善不良生活方式,加强锻炼,并增加相关实验室及辅助医疗检查,让更多的高危患者从二级预防中获益。但SII与CVD发生发展的具体机制尚不明确,未来需要更多前瞻性研究深入验证,最终服务临床,使患者受益。

NOTES

*通讯作者。

参考文献

[1] Yusuf, S., Joseph, P., Rangarajan, S., et al. (2020) Modifiable Risk Factors, Cardiovascular Disease, and Mortality in 155 722 Individuals from 21 Highincome, Middle-Income, and Low-Income Countries (PURE): A Prospective Cohort Study. Lancet, 395, 795-808.
https://doi.org/10.1016/S0140-6736(19)32008-2
[2] 《中国心血管健康与疾病报告2022》编写组. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国心血管杂志, 2023, 28(4): 297-312.
[3] 《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告2021》概述[J]. 中国心血管病研究, 2022, 20(7): 577-596.
[4] Kaplan, R.C. and Frishman, W.H. (2001) Systemic Inflammation as a Cardiovascular Disease Risk Factor and as a Potential Target for Drug Therapy. Heart Disease, 3, 326-332.
https://doi.org/10.1097/00132580-200109000-00009
[5] Madjid, M. and Fatemi, O. (2013) Components of the Complete Blood Count as Risk Predictors for Coronary Heart Disease: In-Depth Review and Update. Texas Heart Institute Journal, 40, 17-29.
[6] Wolf, D. and Ley, K. (2019) Immunity and Inflammation in Atherosclerosis. Circulation Research, 124, 315-327.
https://doi.org/10.1161/CIRCRESAHA.118.313591
[7] Hu, B., Yang, X.R., Xu, Y., Sun, Y.F., Sun, C., Guo, W., Zhang, X., Wang, W.M., Qiu, S.J., Zhou, J. and Fan, J. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222.
https://doi.org/10.1158/1078-0432.CCR-14-0442
[8] Chen, J.H., Zhai, E.T., Yuan, Y.J., et al. (2017) Systemic Immune-Inflammation Index for Predicting Rognosis of Colorectal Cancer. World Journal of Gastroenterology, 23, 6261-6272.
https://doi.org/10.3748/wjg.v23.i34.6261
[9] 孙晓庆, 宗明园, 傅露. 系统免疫炎症指数对非小细胞肺癌患者预后的预测作用[J]. 华南国防医学杂志, 2021, 35(12): 866-870.
[10] 祝梦娇, 罗昆仑, 芮小平, 等. 系统免疫炎症指数在三阴性乳腺癌复发转移中的预测价值[J]. 中国临床新医学, 2021, 14(3): 302-307.
[11] Biyik, M., Biyik, Z., Asil, M. and Keskin, M. (2022) Systemic Inflammation Response Index and Systemic Immune Inflammation Index Are Associated with Clinical Outcomes in Patients with Acute Pancreatitis? Journal of Investigative Surgery, 35, 1613-1620.
https://doi.org/10.1080/08941939.2022.2084187
[12] Xu, M., Chen, R., Liu, L., Liu, X., Hou, J., Liao, J., Zhang, P., Huang, J., Lu, L., Chen, L., Fan, M., Chen, X., Zhu, X., Liu, B., Hu, P. (2021) Systemic Immune-Inflammation Index and Incident Cardiovascular Diseases among Middle-Aged and Elderly Chinese Adults: the Dongfeng-Tongji Cohort Study. Atherosclerosis, 323, 20-29.
https://doi.org/10.1016/j.atherosclerosis.2021.02.012
[13] Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M.L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E.A.E., Azizi, M., Benetos, A., Borghi, C., Hitij, J.B., Cifkova, R., Coca, A., Cornelissen, V., Cruickshank, J.K., Cunha, P.G., Danser, A.H.J., Pinho, R.M., Delles, C., Dominiczak, A.F., Dorobantu, M., Doumas, M., Fernández-Alfonso, M.S., Halimi, J.M., Járai, Z., Jelaković, B., Jordan, J., Kuznetsova, T., Laurent, S., Lovic, D., Lurbe, E., Mahfoud, F., Manolis, A., Miglinas, M., Narkiewicz, K., Niiranen, T., Palatini, P., Parati, G., Pathak, A., Persu, A., Polonia, J., Redon, J., Sarafidis, P., Schmieder, R., Spronck, B., Stabouli, S., Stergiou, G., Taddei, S., Thomopoulos, C., Tomaszewski, M., Van De Borne, P., Wanner, C., Weber, T., Williams, B., Zhang, Z.Y. and Kjeldsen, S.E. (2023) 2023 ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension, 41, 1874-2071.
https://doi.org/10.1097/HJH.0000000000003480
[14] 国家心血管病中心国家基本公共卫生服务项目基层高血压管理办公室, 国家基层高血压管理专家委员会. 国家基层高血压防治管理指南2020版[J]. 中国循环杂志, 2021, 36(3): 209-220.
[15] Madhur, M.S., Elijovich, F., Alexander, M.R., Pitzer, A., Ishimwe, J., Van Beusecum, J.P., Patrick, D.M., Smart, C.D., Kleyman, T.R., Kingery, J., et al. (2021) Hypertension: Do Inflammation and Immunity Hold the Key to Solving This Epidemic? Circulation Research, 128, 908-933.
https://doi.org/10.1161/CIRCRESAHA.121.318052
[16] Harrison, D.G., Coffman, T.M. and Wilcox, C.S. (2021) Pathophysiology of Hypertension: The Mosaic Theory and Beyond. Circulation Research, 128, 847-863.
https://doi.org/10.1161/CIRCRESAHA.121.318082
[17] Bartoloni, E., Alunno, A., Valentini, V., Luccioli, F., Valentini, E., La Paglia, G., et al. (2017) Role of Inflammatory Diseases in Hypertension. High Blood Pressure & Cardiovascular Prevention, 24, 353-361.
https://doi.org/10.1007/s40292-017-0214-3
[18] Jin, N., Huang, L., Hong, J., Zhao, X., Hu, J., Wang, S., Chen, X., Rong, J. and Lu, Y. (2023) The Association between Systemic Inflammation Markers and the Prevalence of Hypertension. BMC Cardiovascular Disorders, 23, Article No. 615.
https://doi.org/10.1186/s12872-023-03661-6
[19] Inanc, I.H. and Sabanoglu, C. (2022) Systemic Immune-Inflammation Index as a Predictor of Asymptomatic Organ Damage in Patients with Newly Diagnosed Treatment-Naive Hypertension. Revista de Investigación Clínica, 74, 258-267.
https://doi.org/10.24875/RIC.22000167
[20] Akyüz, A. and Işık, F. (2022) Systemic Immune-Inflammation Index: A Novel Predictor for Non-Dipper Hypertension. Cureus, 14, e28176.
https://doi.org/10.7759/cureus.28176
[21] Hansson, G.K. (2005) Inflammation, Atherosclerosis, and Coronaryartery Disease. The New England Journal of Medicine, 353, 429-430.
https://doi.org/10.1056/NEJM200507283530425
[22] Marziano, C., Genet, G. and Hirschi, K.K. (2021) Vascular Endothelial Cell Specification in Health and Disease. Angiogenesis, 24, 213-236.
https://doi.org/10.1007/s10456-021-09785-7
[23] Ross, R. (1999) Atherosclerosis—An Inflammatory Disease. The New England Journal of Medicine, 340, 115-126.
https://doi.org/10.1056/NEJM199901143400207
[24] 李丹丹, 梅俊, 周庆兵, 等. 固有免疫介导的炎症反应在动脉粥样硬化发病机制中的研究进展[J]. 中国动脉硬化杂志, 2022, 30(1): 71-76.
[25] Koenen, R.R. and Binder, C.J. (2020) Platelets and Coagulation Factors: Established and Novel Roles in Atherosclerosis and Atherothrombosis. Atherosclerosis, 307, 78-79.
https://doi.org/10.1016/j.atherosclerosis.2020.07.008
[26] Çırakoğlu, Ö.F. and Yılmaz, A.S. (2021) Systemic Immune-Inflammation Index Is Associated with Increased Carotid Intima-Media Thickness in Hypertensive Patients. Clinical and Experimental Hypertension, 43, 565-571.
https://doi.org/10.1080/10641963.2021.1916944
[27] Silvestre-Roig, C., Braster, Q., Ortega-Gomez, A. and Soehnlein, O. (2020) Neutrophils as Regulators of Cardiovascular Inflammation. Nature Reviews Cardiology, 17, 327-340.
https://doi.org/10.1038/s41569-019-0326-7
[28] 闵轩, 王凯阳, 宁怡, 等. 系统免疫炎症指数与冠心病患者冠状动脉病变程度的相关性研究[J]. 中国心血管杂志, 2023, 28(3): 228-233.
[29] 王浩宇, 陈玉成, 郑蓉, 等. 缺血预适应后心肌水肿与水通道Aquaporin-1蛋白表达变化的关系[J]. 四川医学, 2007, 28(5): 464-467.
[30] Huang, J., Zhang, Q., Wang, R., Ji, H., Chen, Y., Quan, X. and Zhang, C. (2019) Systemic Immune-Inflammatory Index Predicts Clinical Outcomes for Elderly Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention. Medical Science Monitor, 25, 9690-9701.
https://doi.org/10.12659/MSM.919802
[31] Özkan, U., Gürdoğan, M., Öztürk, C., Demir, M., Akkuş, Ö.F., Yılmaz, E. and Altay, S. (2022) Systemic Immune-Inflammation Index: A Novel Predictor of Coronary Thrombus Burden in Patients with Non-ST Acute Coronary Syndrome. Medicina, 58, Article 143.
https://doi.org/10.3390/medicina58020143
[32] 刘诗彤. 系统免疫炎症指数与STEMI患者经皮冠状动脉介入术后发生慢血流/无复流的相关性研究[D]: [硕士学位论文]. 大连: 大连医科大学, 2022.
[33] Kelesoglu, S., Yilmaz, Y., Elcık, D., Çetınkaya, Z., Inanc, M.T., Dogan, A., Oguzhan, A. and Kalay, N. (2021) Systemic Immune Inflammation Index: A Novel Predictor of Contrast-Induced Nephropathy in Patients with Non-ST Segment Elevation Myocardial Infarction. Angiology, 72, 889-895.
https://doi.org/10.1177/00033197211007738
[34] Bağcı, A., Aksoy, F. and Baş, H.A. (2022) Systemic Immune-Inflammation Index May Predict the Development of Contrast-Induced Nephropathy in Patients with ST-Segment Elevation Myocardial Infarction. Angiology, 73, 218-224.
https://doi.org/10.1177/00033197211030053
[35] Bozkurt, B., Coats, A.J.S., Tsutsui, H., Abdelhamid, C.M., Adamopoulos, S., Albert, N., Anker, S.D., Atherton, J., Böhm, M., Butler, J., Drazner, M.H., Michael, Felker, G., Filippatos, G., Fiuzat, M., Fonarow, G.C., Gomez-Mesa, J.E., Heidenreich, P., Imamura, T., Jankowska, E.A., Januzzi, J., Khazanie, P., Kinugawa, K., Lam, C.S.P., Matsue, Y., Metra, M., Ohtani, T., Francesco Piepoli, M., Ponikowski, P., Rosano, G.M.C., Sakata, Y., Seferović, P., Starling, R.C., Teerlink, J.R., Vardeny, O., Yamamoto, K., Yancy, C., Zhang, J. and Zieroth, S. (2021) Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. European Journal of Heart Failure, 23, 352-380.
https://doi.org/10.1002/ejhf.2115
[36] 张健, 张宇辉, 周蕾. 国家心力衰竭指南2023 (精简版) [J]. 中国循环杂志, 2023, 38(12): 1207-1238.
[37] Li, Y., Sun, X.L., Qiu, H., et al. (2021) Long-Term Outcomes and Independent Predictors of Mortality in Patients Presenting to Emergency Departments with Acute Heart Failure in Beijing: A Multicenter Cohort Study with a 5-Year Follow-Up. Chinese Medical Journal, 134, 1803-1811.
https://doi.org/10.1097/CM9.0000000000001617
[38] NHFA CSANZ Heart Failure Guidelines Working Group, Atherton, J.J., Sindone, A., De Pasquale, C.G., Driscoll, A., MacDonald, P.S., Hopper, I., Kistler, P.M., Briffa, T., Wong, J., Abhayaratna, W., Thomas, L., Audehm, R., Newton, P., O’Loughlin, J., Branagan, M. and Connell, C. (2018) National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Chinese Medical Journal, 27, 1123-1208.
https://doi.org/10.1016/j.hlc.2018.06.1042
[39] Mueller, C., McDonald, K., De Boer, R.A., Maisel, A., Cleland, J.G.F., Kozhuharov, N., Coats, A.J.S., Metra, M., Mebazaa, A., Ruschitzka, F., Lainscak, M., Filippatos, G., Seferovic, P.M., Meijers, W.C., Bayes-Genis, A., Mueller, T., Richards, M., Januzzi Jr., J.L. and Heart Failure Association of the European Society of Cardiology (2019) Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations. European Journal of Heart Failure, 21, 715-731.
https://doi.org/10.1002/ejhf.1494
[40] Johannes, C., Martin, K., Theresa, A., et al. (2011) Quantifying the Added Value of BNP in Suspected Heart Failure in General Practice: An Individual Patient Data Meta-Analysis. Heart, 97, 959-963.
https://doi.org/10.1136/hrt.2010.220426
[41] Zhang, Y., Bauersachs, J. and Langer, H.F. (2017) Immune Mechanisms in Heart Failure. European Journal of Heart Failure, 19, 1379-1389.
https://doi.org/10.1002/ejhf.942
[42] Yuan, M., Ren, F. and Gao, D. (2022) The Value of SII in Predicting the Mortality of Patients with Heart Failure. Disease Markers, 2022, Article ID: 3455372.
https://doi.org/10.1155/2022/3455372
[43] 黎晨辉, 杨少芬, 卢庆莉, 等. 系统免疫炎症指数与慢性心力衰竭急性发作患者院内死亡的相关性研究[J]. 心肺血管病杂志, 2021, 40(7): 658-662.
[44] Del Buono, M.G., Moroni, F., Montone, R.A., Azzalini, L., Sanna, T. and Abbate, A. (2022) Ischemic Cardiomyopathy and Heart Failure after Acute Myocardial Infarction. Current Cardiology Reports, 24, 1505-1515.
https://doi.org/10.1007/s11886-022-01766-6
[45] 杨少琦, 杨洋, 邓丽娜, 等. 系统免疫炎症指数对老年射血分数减低型心力衰竭病人下肢深静脉血栓形成的预测价值[J]. 实用老年医学, 2023, 37(7): 695-699.
[46] Chioncel, O., Parissis, J., Mebazaa, A., et al. (2020) Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock—A Position Statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 22, 1315-1341.
https://doi.org/10.1002/ejhf.1922
[47] Brener, M.I., Rosenblum, H.R. and Burkhoff, D. (2020) Pathophysiology and Advanced Hemodynamic Assessment of Cardiogenic Shock. Methodist DeBakey Cardiovascular Journal, 16, 7-15.
https://doi.org/10.14797/mdcj-16-1-7
[48] 张松. 心源性休克诊治进展及指南解读[J]. 医学研究杂志, 2017, 46(10): 1-3, 17.
[49] Acharya, D. (2018) Predictors of Outcomes in Myocardial Infarction and Cardiogenic Shock. Cardiology in Review, 26, 255-266.
https://doi.org/10.1097/CRD.0000000000000190
[50] Peng, Y., Huang, W., Shi, Z., Chen, Y. and Ma, J. (2020) Positive Association between Systemic Immune-Inflammatory Index and Mortality of Cardiogenic Shock. Clinica Chimica Acta, 511, 97-103.
https://doi.org/10.1016/j.cca.2020.09.022